Alterity Therapeutics (ATHE) Long-Term Deferred Tax (2017 - 2025)

Alterity Therapeutics' Long-Term Deferred Tax history runs 9 years deep, the most recent figure standing at $31.9 million for Q2 2025.

• On a quarterly basis, Long-Term Deferred Tax rose 1.51% year-over-year to $31.9 million in Q2 2025; TTM through Jun 2025 was $31.9 million, a 1.51% increase from a year earlier, with the FY2025 full-year figure at $31.9 million, up 1.51% from the prior year.
• Long-Term Deferred Tax climbed to $31.9 million in Q2 2025 per ATHE's latest filing, from $31.5 million in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $31.9 million in Q2 2025 and bottomed at $29.4 million in Q2 2023.
• The 5-year median for Long-Term Deferred Tax is $31.5 million (2024), against an average of $30.8 million.
• Across the five-year window, Long-Term Deferred Tax rose 20.68% in 2021 and decreased 7.03% in 2022, its largest moves.
• Year by year, Long-Term Deferred Tax stood at $31.7 million in 2021, then decreased by 7.03% to $29.5 million in 2022, then retreated by 0.23% to $29.4 million in 2023, then advanced by 6.89% to $31.5 million in 2024, then advanced by 1.51% to $31.9 million in 2025.
• Per Business Quant, the three latest ATHE Long-Term Deferred Tax figures stand at $31.9 million (Q2 2025), $31.5 million (Q2 2024), and $29.4 million (Q2 2023).